Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntibioticsImipenem/Cilastatin250-500mg IV Q12HAdminister Post-HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
299/35820-701413-210.17-0.368-84/41-6521-90/38-63 (low flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Berman S, Sugihara J, Nakamura J et al. Multiple-dose study of imipenem/cilastatin in patients with end-stage renal disease undergoing long-term hemodialysis. The American journal of medicine 1985; 78(6A), 113-6.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL:,
  • Gibson T, Demetriades J, Bland J. Imipenem/Cilastatin: Pharmacokinetic Profile in Renal Insufficiency. Medicine 1985; 78(Suppl 6A), 54-61.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Konishi K, Suzuki H, Saruta T et al. Removal of Imipenem and Cilastatin by Hemodialysis in Patients with End-Stage Renal Failure. Antimicrobial agents and chemotherapy 1991; 35(8), 1616-22.
  • Matzke G. Status of Hemodialysis of Drugs in 2002. Journal of Pharmacy Practice 2002; 15(5), 405-418.
  • Verpooten G, Verbist L, Buntinx A, Entwistle L, Jones K, De Broe, M. The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure. British journal of clinical pharmacology 1984; 18(2), 183-93.